Personal Finance

RayzeBio Stock Surges 101% on $4.1 Billion Takeover by Bristol Myers

Bristol Myers Squibb will acquire radiopharmaceutical therapeutics company RayzeBio for $62.50 a share in cash.

Continue reading this article with a Barron’s subscription.

View Options

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button